Simeprevir

Simeprevir is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • In combination with Peg-IFN and ribavirin, simeprevir is FDA indicated for the treatment of HCV genotype 1 in patients with compensated liver disease (including cirrhosis).
  • Since lower efficacy has been observed in some studies in patients infected with HCV genotype 1a with NS3 Q80K* polymorphism, screening for this polymorphism at baseline is recommended if simeprevir use is planned.
  • If NS3 Q80K polymorphism is detected, use of an alternative directly acting HCV regimen should be considered.

*In clinical trials, prevalence of Q80K polymorphism observed in 30% patients infected with HCV genotype1a and only 0.5% in patients infected with HCV genotype 1b.

NON-FDA APPROVED USES

Simeprevir plus sofosbuvir +/- ribavirin is a recommended first line regimen for the treatment of HCV genotype 1a and 1b. NS3 Q80K polymorphism for genotype 1a did not significantly impact sustained virologic response to this regimen.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • In combination with Peg-IFN and ribavirin, simeprevir is FDA indicated for the treatment of HCV genotype 1 in patients with compensated liver disease (including cirrhosis).
  • Since lower efficacy has been observed in some studies in patients infected with HCV genotype 1a with NS3 Q80K* polymorphism, screening for this polymorphism at baseline is recommended if simeprevir use is planned.
  • If NS3 Q80K polymorphism is detected, use of an alternative directly acting HCV regimen should be considered.

*In clinical trials, prevalence of Q80K polymorphism observed in 30% patients infected with HCV genotype1a and only 0.5% in patients infected with HCV genotype 1b.

NON-FDA APPROVED USES

Simeprevir plus sofosbuvir +/- ribavirin is a recommended first line regimen for the treatment of HCV genotype 1a and 1b. NS3 Q80K polymorphism for genotype 1a did not significantly impact sustained virologic response to this regimen.

There's more to see -- the rest of this entry is available only to subscribers.